Risk of Hospitalized Infection With DMARD or TNF-I Therapy for Ankylosing Spondylitis

October 17, 2018

Concerns have been raised in the past about the possibility of infection caused by immune suppression.

Moura and colleagues in Canada found no increase in risk of hospitalized infection in patients with ankylosing spondylitis (AS) who take disease-modifying antirheumatic (DMARDs) or anti-tumor necrosis factor (TNF-I) drugs.¹ Thumb through the slides for the details of their study and the take-home points for physicians.

(Image: ©sfam_photo/Shutterstock.com)

NSAIDs, nonsteroidal anti-inflammatory drugs; TNF, tumor necrosis factor.

AS, ankylosing spondylitis; DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; SSZ, sulfasalazine; TNF-I, tumor necrosis factor inhibitor.

DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor.

AS, ankylosing spondylitis; DMARD, disease-modifying antirheumatic drug; TNF-I, tumor necrosis factor inhibitor.

Reference

1. Moura CS, Rahme E, Maksymowych WP, et al. Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis. Scand J Rheumatol. 2018 Aug 16:1-7. doi: 10.1080/03009742.2018.1470253. [Epub ahead of print]

Related Content:

Risk of Hospitalized Infection With DMARD or TNF-I Therapy for Ankylosing Spondylitis

Gregory M. Weiss, MD